BECOME A MEMBER
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.
Get Involved
TAKE OUR COURSES
The curriculum brings hands-on practical guidance on how to develop personalized treatment regimens and more.
Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse.
Authors: J H Allen, G M de Moore, R Heddle, J C Twartz
Gut, November 2004
—
BACKGROUND AND AIMS: To explore the association between chronic cannabis abuse and a cyclical vomiting illness that presented in a series of cases in South Australia. METHODS: Nineteen patients were identified with chronic cannabis abuse and a cyclical vomiting illness. For le…
The endocannabinoid-CB(1) receptor system in pre- and postnatal life.
Authors: Ester Fride
European Journal of Pharmacology, October 2004
—
Recent research suggests that the endogenous cannabinoids (“endocannabinoids”) and their cannabinoid receptors have a major influence during pre- and postnatal development. First, high levels of the endocannaboid anandamide and cannabinoid receptors are present in the preimpla…
Delta-9 tetrahydrocannabinol (THC) inhibits lytic replication of gamma oncogenic herpesviruses in vitro.
Authors: Maria M. Medveczky, Tracy A. Sherwood, Thomas W. Klein, Herman Friedman, Peter G. Medveczky
BMC Medicinevolume, 15 September 2004
—
BACKGROUND: The major psychoactive cannabinoid compound of marijuana, delta-9 tetrahydrocannabinol (THC), has been shown to modulate immune responses and lymphocyte function. After primary infection the viral DNA genome of gamma herpesviruses persists in lymphoid cell nuclei i…
Survey on cannabis use in Parkinson’s disease: subjective improvement of motor symptoms.
Authors: Katerina Venderova, Evzen Růzicka, Viktor Vorısek, Peter Visnovsky
Movement Disorders, September 2004
—
An anonymous questionnaire sent to all patients attending the Prague Movement Disorder Centre revealed that 25% of 339 respondents had taken cannabis and 45.9% of these described some form of benefit.
An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.
Authors: C. M. Brady, R. DasGupta, C. Dalton, O. J. Wiseman, K. J. Berkley, C. J. Fowler
Multiple Sclerosis Journal, 1 August 2004
—
The majority of patients with multiple sclerosis (MS) develop troublesome lower urinary tract symptoms (LUTS). Anecdotal reports suggest that cannabis may alleviate LUTS, and cannabinoid receptors in the bladder and nervous system are potential pharmacological targets. In an o…
Prenatal marijuana and alcohol exposure and academic achievement at age 10.
Authors: Lidush Goldschmidt, Gale A Richardson, Marie D Cornelius, Nancy L Day
Neurotoxicology and Teratology, July-August 2004
—
The effects of prenatal marijuana and alcohol exposure on school achievement at 10 years of age were examined. Women were interviewed about their substance use at the end of each trimester of pregnancy, at 8 and 18 months, and at 3, 6, 10, 14, and 16 years. The women were of l…
Cannabis, cannabinoids and reproduction.
Authors: Boram Park, John M. McPartland, Michelle Glass
Prostaglandins, Leukotrienes and Essential Fatty Acids, February 2004
—
In most countries Cannabis is the most widely used illegal drug. Its use during pregnancy in developed nations is estimated to be approximately 10%. Recent evidence suggests that the endogenous cannabinoid system, now consisting of two receptors and multiple endocannabinoid li…
The endocannabinoid-CB receptor system: Importance for development and in pediatric disease.
Authors: Ester Fride
Neuro endocrinology letters, February-April 2004
—
Endogenous cannabinoids (endocannabinoids) and their cannabinoid CB1 and CB2 receptors, are present from the early stages of gestation and play a number of vital roles for the developing organism. Although most of these data are collected from animal studies, a role for cannab…
Two hundred and thirteen cases of marijuana toxicoses in dogs.
Authors: Pawel Janczyk, Caroline W Donaldson, Sharon M. Gwaltney
Veterinary and Human Toxicology, February 2004
—
Marijuana (Cannabis sativa) is a commonly used recreational drug among humans; animals may be exposed following ingestion or accidental inhalation of smoke. From January 1998 to January 2002, 213 incidences were recorded of dogs that developed clinical signs following oral exp…
The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy.
Authors: Melisa J. Wallace, Robert E. Blair, Katherine W. Falenski, Billy R. Martin, Robert J. DeLorenzo
Journal of Pharmacology and Experimental Therapeutics, October 2003
—
Several lines of evidence suggest that cannabinoid compounds are anticonvulsant. However, the anticonvulsant potential of cannabinoids and, moreover, the role of the endogenous cannabinoid system in regulating seizure activity has not been tested in an in vivo model of epileps…
Cannabinoids reduce symptoms of Tourette’s syndrome.
Authors: Kirsten R Müller-Vahl
Expert Opinion on Pharmacotherapy, October 2003
—
Currently, the treatment of Tourette’s syndrome (TS) is unsatisfactory. Therefore, there is expanding interest in new therapeutical strategies. Anecdotal reports suggested that the use of cannabis might improve not only tics, but also behavioural problems in patients with TS…
Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study.
Authors: Igor Grant, Raul Gonzalez, Catherine L. Carey, Loki Natarajan, Tanya Wolfson
Journal of the International Neuropsychological Society, July 2003
—
The possible medicinal use of cannabinoids for chronic diseases emphasizes the need to understand the long-term effects of these compounds on the central nervous system. We provide a quantitative synthesis of empirical research pertaining to the non-acute (residual) effects of…